Study Evaluating the Effects of AIR645 on Allergen-Induced Airway Responses in Subjects With Mild Atopic Asthma

Altair Therapeutics

Status and phase: Completed; Phase 2

Conditions: Asthma

Treatments: Drug: AIR645; Drug: Physiologic saline solution

Study type: Interventional

Funder types: Industry

Identifiers

NCT00941577

AIR645-CS2

Details and patient eligibility

About

To assess the efficacy of inhaled AIR645 in the suppression of the Asthmatic Responses in subjects with mild asthma inhaling an allergen.

Enrollment: 30 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Men and women with well controlled mild allergic asthma, aged 18 to 65 years
• Only asthma med is short-acting bronchodilator used not more than twice weekly
• FEV1 greater than 70% predicted and a demonstrated baseline late response to allergen induction

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

30 participants in 2 patient groups, including a placebo group

AIR645

Experimental group

Description:

AIR645 (an IL-4/IL-13 dual cytokine signaling inhibitor) solution (diluent: physiologic saline solution)

Treatment:

Drug: AIR645

Physiologic saline solution

Placebo Comparator group

Description:

Physiologic saline solution

Treatment:

Drug: Physiologic saline solution